April 6, 2017 09:22 AM EDT

Study highlights the FDA’s speed in approving cancer drugs as a new commish looks to rev up reviews

John Carroll

Editor & Founder

During his confirmation hearing on Wednesday Scott Gottlieb emphasized that he would start his new job as FDA commissioner by focusing on different parts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Study highlights the FDA’s speed in approving cancer drugs as a new commish looks to rev up reviews

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Rare disease biopharma companies weigh in on FDA's new innovation hub

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Study high­lights the FDA’s speed in ap­prov­ing can­cer drugs as a new com­mish looks to rev up re­views

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Study highlights the FDA’s speed in approving cancer drugs as a new commish looks to rev up reviews